Key IL-13 Skin and Itch Data in Moderate-to-Severe AD.

0 SAR
Checkout

Overview

In this video, Prof. Gil Yosipovitch reviews key skin and itch data supporting the efficacy
of Ebglyss® (lebrikizumab), an IL-13 inhibitor, in moderate-to-severe atopic dermatitis.
He outlines the standard endpoints used in studies of IL-13 and IL-13/4 inhibitors and
explains the concept of a stable response — defined as no or minimal fluctuations with
treatment — across key measures of skin clearance and itch relief in moderate-to-severe
AD.


This Class for

  • Clinical Pharmacy
  • Pharmacy
  • Physician
  • Resident / Fellow

What I will learn?

  • ● Review the key skin and itch efficacy data for lebrikizumab in
    moderate-to-severe atopic dermatitis.
    ● Describe the standard endpoints used in studies of IL-13 and IL-13/4
    inhibitors in moderate-to-severe atopic dermatitis.
    ● Define a stable response as no or minimal fluctuations with treatment.
    ● Explain the clinical relevance of maintaining a stable response in
    moderate-to-severe atopic dermatitis.

    Disclaimer

    This content is approved by Eli Lilly and Company (“Lilly”). This content is intellectual property of Lilly and its reproduction needs Lilly's prior permission
    (This information/content is intended to Health Care Providers only)

    For adverse events and safety reporting: email: saudi_pharmacovigilance@lilly.com

    24 /7 mobile: +966 567 868 843, Working hours Tel: +966 11 461 7800 , Ext: 1

    For Lilly product information: email: SAUDI_MEDINFOQUERIES@lilly.com

    For further information, please contact:

    Eli Lilly and Company, Scientific Office P.O. Box 92120 Riyadh 11653, Kingdom of Saudi Arabia. Tel: +966 11 461 7800 Fax: +966 111 217 9900 email: Saudi_Pharmacovigilance@lilly.com

    PP-LK-SA-0196


Related Classes